


Towards Rational Design of Policies and Practices to Enable Clinical Translation of Novel Cancer Biotherapeutics in Canada

January 1, 2016 to March 31, 2020

Highlights

- Addresses significant economic, legal and health system challenges that face the translation of cancer biotherapeutics into the clinic
- Positions BioCanRx-developed biotherapeutics for uptake into the health care system
- Integrates understanding of regulatory and reimbursement challenges
- Provides patient information on reputable clinical trials of cancer biotherapeutics in North America



About the project

BioCanRx aims to accelerate the development of cost-effective and curative cancer biotherapeutics for the benefit of Canadian patients and the Canadian economy. However, its exciting R&D program faces significant non-scientific challenges that must be addressed.

The proposed program of work focuses on four interrelated challenges:

- (1) Canada's ability to compete within a global clinical R&D environment;
- (2) the development of collaborative R&D models to develop effective cancer biotherapeutics;
- (3) the development of models for clinical implementation; and
- (4) the development of new reimbursement paradigms to advance health system adoption of curative therapies. The team will use and develop legal, policy, and economic analyses to examine these issues.


In supporting forward-looking social science research, BioCanRx is positioned to lead in the formulation of policy, regulations and systems innovations required to bring novel biotherapies to cancer patients in the clinic.

Key investigator


Dr. Tania **Bubela**

SFU

Project investigators



BioCanRx
\$346,386
approved on
January 5, 2016



The power to kill cancer lies within us.
Let's tell our bodies how.

